Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunotech Biopharm Ltd ( (HK:6978) ) has shared an update.
Immunotech Biopharm Ltd has announced a proposed rights issue to raise up to HK$307.84 million through the issuance of up to 123,135,430 Rights Shares. The rights issue is underwritten on a best-effort basis by Maxa Asset Management Limited and will proceed regardless of the subscription level, with any unsubscribed shares not being issued. This move is part of the company’s strategy to strengthen its financial position without requiring shareholder approval, as it complies with the relevant listing rules.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies. The company is listed on the Hong Kong Stock Exchange and is involved in the biotechnology sector.
Average Trading Volume: 1,028,799
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.45B
See more data about 6978 stock on TipRanks’ Stock Analysis page.